Targeted protein degradation combined with PET imaging reveals the role of host PD-L1 in determining anti-PD-1 therapy efficacy
European Journal of Nuclear Medicine and Molecular Imaging · 2024
DOI: 10.1007/s00259-024-06804-9 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, 2024. Verfasst von Jinhong Du und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Medicine, School of Basic Medical Sciences, Peking University Health Science Center, Beijing, 100191, China. Hauptthemen laut MEDLINE: B7-H1 Antigen, Positron-Emission Tomography, Proteolysis. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 48 Literaturangaben. Gefördert von: National Outstanding Youth Science Fund Project of National Natural Science Foundation of China.
Abstract (Originalsprache)
PURPOSE: Immunohistochemical staining of programmed death-ligand 1 (PD-L1) in tumor biopsies acquired through invasive procedures is routinely employed in clinical practice to identify patients who are most likely to benefit from anti-programmed cell death protein 1 (PD-1) therapy. Nevertheless, PD-L1 expression is observed in various cellular subsets within tumors and their microenvironments, including tumor cells, dendritic cells, and macrophages. The impact of PD-L1 expression across these different cell types on the responsiveness to anti-PD-1 treatment is yet to be fully understood. METHODS: We synthesized polymer-based lysosome-targeting chimeras (LYTACs) that incorporate both PD-L1-targeting motifs and liver cell-specific asialoglycoprotein receptor (ASGPR) recognition elements. Small-animal positron emission tomography (PET) imaging of PD-L1 expression was also conducted using a PD-L1-specific radiotracer 89Zr-αPD-L1/Fab. RESULTS: The PD-L1 LYTAC platform was capable of specifically degrading PD-L1 expressed on liver cancer cells through the lysosomal degradation pathway via ASGPR without impacting the PD-L1 expression on host cells. When coupled with whole-body PD-L1 PET imaging, our studies revealed that host cell PD-L1, rather than tumor cell PD-L1, is pivotal in the antitumor response to anti-PD-1 therapy in a mouse model of liver cancer. CONCLUSION: The LYTAC strategy, enhanced by PET imaging, has the potential to surmount the limitations of knockout mouse models and to provide a versatile approach for the selective degradation of target proteins in vivo. This could significantly aid in the investigation of the roles and mechanisms of protein functions associated with specific cell subsets in living subjects.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiation Medicine, School of Basic Medical Sciences, Peking University Health Science Center, Beijing, 100191, China.
- Department of Nuclear Medicine, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), NMPA Key Laboratory for Research and Evaluation of Radiopharmaceuticals, Peking University Can…
- Department of Nuclear Medicine, Peking University Third Hospital, Beijing, 100191, China.
- Department of Nuclear Medicine, Peking University Third Hospital, Beijing, 100191, China. tsy1997@126.com.
- Department of Radiation Medicine, School of Basic Medical Sciences, Peking University Health Science Center, Beijing, 100191, China. liuzf@bjmu.edu.cn.
- Department of Nuclear Medicine, Peking University Third Hospital, Beijing, 100191, China. liuzf@bjmu.edu.cn.
ORCID-Profile: Zhaofei Liu
Förderung
- National Outstanding Youth Science Fund Project of National Natural Science Foundation of China
Zitieren
APA
Du, J., Han, S., Zhou, H., Wang, J., Wang, F., Zhao, M., Song, R., Li, K., Zhu, H., Zhang, W., Yang, Z., & Liu, Z. (2024). Targeted protein degradation combined with PET imaging reveals the role of host PD-L1 in determining anti-PD-1 therapy efficacy. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-024-06804-9
Vancouver
Du J, Han S, Zhou H, Wang J, Wang F, Zhao M, et al. Targeted protein degradation combined with PET imaging reveals the role of host PD-L1 in determining anti-PD-1 therapy efficacy. European Journal of Nuclear Medicine and Molecular Imaging. 2024. doi:10.1007/s00259-024-06804-9
BibTeX
@article{Du2024,
author = {Du, Jinhong and Han, Shu and Zhou, Haoyi and Wang, Jianze and Wang, Feng and Zhao, Meixin and Song, Rui and Li, Kui and Zhu, Hua and Zhang, Weifang and Yang, Zhi and Liu, Zhaofei},
title = {Targeted protein degradation combined with PET imaging reveals the role of host PD-L1 in determining anti-PD-1 therapy efficacy},
journal = {European Journal of Nuclear Medicine and Molecular Imaging},
year = {2024},
doi = {10.1007/s00259-024-06804-9}
}
EUVIMED